BioNTech sticks with COVID vaccine outlook amid sharp revenue declines

Like so many other drugmakers, BioNTech saw its total revenues drop significantly due to the waning demand for COVID-19 vaccines and treatments.

The German biotech reported €167.7 million in total revenues for the quarter, down from €3.2 billion this time last year.